July 20, 2016 by 2012pharmaceutical
Groups Launcher and Group Manager: Aviva Lev-Ari, PhD, RN
Posted in 3D Printing for Medical Application, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceuticall R&D Informatics, Clinical Genomics, Cancer Informatics, BioTechnology - Venture Creation, Venture Capital, CANCER BIOLOGY & Innovations in Cancer Therapy, Cardiac and Cardiovascular Surgical Procedures, Cardiovascular Research, Computational Biology/Systems and Bioinformatics, CRISPR/Cas9 & Gene Editing, DNA repair, Drug Delivery Platform Technology, Epigenetics and Environmental Factors, FDA Regulatory Affairs, Frontiers in Cardiology and Cardiovascular Disorders, Genome Biology, Genomic Testing: Methodology for Diagnosis, Global Partnering & Biotech Investment, Health Law & Patient Safety, HealthCare IT, Human Immune System in Health and in Disease, Immuno-Oncology & Genomics, Immunodiagnostics, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough, International Global Work in Pharmaceutical, Interventional Oncology: Radiofrequency Ablation, Transarterial Chemoembolization, Microwave Ablation and Irreversible Electroporation (IRE), Interviews with Scientific Leaders, Investment in Technological Breakthrough, Medical Devices R&D and Inventions, Origins of Cardiovascular Disease, Pharmacotherapy of Cardiovascular Disease | Leave a Comment
Fill in your details below or click an icon to log in:
You are commenting using your WordPress.com account. ( Log Out / Change )
You are commenting using your Twitter account. ( Log Out / Change )
You are commenting using your Facebook account. ( Log Out / Change )
You are commenting using your Google+ account. ( Log Out / Change )
Connecting to %s
Notify me of new comments via email.
Enter your email address to follow this blog and receive notifications of new posts by email.
Join 2,238 other followers
Blog at WordPress.com.